Oragenics Inc.

Oragenics Reports 8 study drug doses in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury

Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION